VIR vs. MLTX, IMVT, LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, and MIRM
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
In the previous week, MoonLake Immunotherapeutics had 9 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for MoonLake Immunotherapeutics and 2 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.23 beat MoonLake Immunotherapeutics' score of 0.50 indicating that Vir Biotechnology is being referred to more favorably in the news media.
MoonLake Immunotherapeutics presently has a consensus target price of $78.71, indicating a potential upside of 70.86%. Vir Biotechnology has a consensus target price of $32.86, indicating a potential upside of 506.22%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.
93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
MoonLake Immunotherapeutics received 14 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 82.02% of users gave MoonLake Immunotherapeutics an outperform vote while only 57.28% of users gave Vir Biotechnology an outperform vote.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Vir Biotechnology. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Vir Biotechnology's return on equity.
Summary
MoonLake Immunotherapeutics beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy VIR Stock Free VIR Stock Alerts